Ozempic, Wegovy, Mounjaro — you've heard the hype. These GLP‑1 receptor agonists were developed for diabetes, but they cause dramatic weight loss. The diabetes drug market research shows that GLP‑1s are the fastest‑growing drug class, with a CAGR above 10%. Why? Because they not only lower blood sugar but also reduce appetite, slow stomach emptying, and even protect the heart.
What's the catch? They're expensive ($1,000+ per month), cause nausea, and are often in short supply due to off‑label use for weight loss. The diabetes drug market trends highlight that injectables are the fastest‑growing route of administration, because GLP‑1s are peptides that can't be taken orally — yet. Several companies are working on oral versions (Eli Lilly's orforglipron, Pfizer's danuglipron).
But GLP‑1s are not for everyone. They're not first‑line for diabetes (metformin is cheaper and safer). And they can cause pancreatitis and gallbladder disease.
The message: if you have Type 2 diabetes and struggle with weight, ask your doctor about GLP‑1s. They're a game‑changer — but they're not magic. Lifestyle changes still matter.
